Abstract:Cell death is attributed to the unrecoverable disturbance of cells exposed to intracellular or extracellular stimulus. Regulated cell death (RCD), also known as programmed cell death (PCD), involves signaling cascades in which effector molecules participate in and play important roles for maintaining organism homeostasis. As a basic biological phenomenon of cells, RCD displays exceptional influence on the occurrence and development of many pathophysiological processes. N6-methyladenosine (m6A) is an important epigenetic modification that regulates RNA fate and subsequent bioprocesses. It occurs extensively on multiple RNA species and is the most abundant internal modification of eukaryotic messenger RNA (mRNA). The abundance of m6A modification is regulated by its methyltransferases and demethylases, and the diverse biological functions of m6A are executed by distinct m6A binding proteins. Accruing evidence shows that m6A modification participates in eukaryotic cell fate transition and determination. In recent years, the disorder of m6A modification status has been observed during the initiation and progression of various RCDs, including classical apoptosis, necroptosis, pyroptosis, and the newly described ferroptosis. Due to the importance of m6A and RCD in cellular and organismal homeostasis, it is worthwhile to recapitulate and organize the current knowledge of the crosstalk between m6A status and RCDs with distinct biochemical and morphological features, as well as immune consequences. In this chapter, we systematically summarize the regulatory networks of m6A modification on RCDs to provide the profiling of m6A-RCD regulatory axis as comprehensively as possible.

Potential applications of N6 -methyladenosine modification in the prognosis and treatment of cancers via modulating apoptosis, autophagy, and ferroptosis

The emerging roles of N6-methyladenosine RNA methylation in human cancers

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

N6-methyladenosine modification: a novel pharmacological target for anti-cancer drug development

Multifaceted Functions of RNA m6A Modification in Modulating Regulated Cell Death

The Roles of M6a RNA Modifiers in Human Cancer

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

N6-methyladenosine methyltransferases: functions, regulation, and clinical potential

Epitranscriptomic M6a Modification in the Stem Cell Field and Its Effects on Cell Death and Survival.

Role of N6-methyladenosine RNA modification in cancer

The potential role of RNA N6-methyladenosine in Cancer progression

Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer

The roles of m<SUP>6</SUP>A RNA modifiers in human cancer

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

N6-methyladenine modification in noncoding RNAs and its function in cancer

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer

M6a Modification: a New Avenue for Anti-Cancer Therapy

Effects of N6-Methyladenosine Modification on Cancer Progression: Molecular Mechanisms and Cancer Therapy

The Roles of N6-methyladenosine and Its Target Regulatory Noncoding RNAs in Tumors: Classification, Mechanisms, and Potential Therapeutic Implications.

Roles and implications of mRNA N 6 ‐methyladenosine in cancer